Why Immix Biopharma (IMMX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine thesis — one sentence
Immix Biopharma is a cash-burning, single-pipeline biotech with weak quality scores and high short interest, offering binary upside only if its lead program delivers.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The pipeline rests on one asset, NXC-201, which is made by third-party CMOs, concentrating both clinical and supply risk. Bear case | NXC-201 advances without manufacturing disruption over the next 12 months. | ↑Improving |
| CounterOutsourced manufacturing and a single-asset pipeline mean one clinical or supply setback could erase most of the company's value. | ||
The business is cash-burning with negative FCF and a quality score of 1.6, below the 4.0 floor. Quality breakdown | Quality score improves above 4.0 only if the company funds operations without heavy dilution. | →Stable |
| CounterFor a pre-revenue biotech, negative FCF is normal and the quality score understates clinical value. | ||
Quarterly EPS has landed in line with estimates, with the latest actual loss of -0.19 matching the -0.19 estimate. Earnings | Quarterly loss stays near -0.19 per share, showing a controlled burn rate. | ↓Deteriorating |
| CounterIn-line losses still mean continuous cash burn that must be funded by new capital. | ||
Short interest of 16% is high, signaling sizeable bearish positioning against the stock. Key risks | Short interest declines as clinical evidence accumulates. | ↑Improving |
| CounterHigh short interest can fuel a squeeze if the lead program reads out well. | ||
Price is below the 200-day average, but that average is still rising at +4.3%/30d, a pullback in an uptrend after a -54% drawdown. Momentum breakdown | Price reclaims the 200-day average while its slope stays positive. | ↓Deteriorating |
| CounterFalling on-balance volume shows distribution, and the momentum score of 3.4 reflects persistent selling. | ||
The pipeline rests on one asset, NXC-201, which is made by third-party CMOs, concentrating both clinical and supply risk.
↑Improving- Expectation
- NXC-201 advances without manufacturing disruption over the next 12 months.
CounterOutsourced manufacturing and a single-asset pipeline mean one clinical or supply setback could erase most of the company's value.
The business is cash-burning with negative FCF and a quality score of 1.6, below the 4.0 floor.
→Stable- Expectation
- Quality score improves above 4.0 only if the company funds operations without heavy dilution.
CounterFor a pre-revenue biotech, negative FCF is normal and the quality score understates clinical value.
Quarterly EPS has landed in line with estimates, with the latest actual loss of -0.19 matching the -0.19 estimate.
↓Deteriorating- Expectation
- Quarterly loss stays near -0.19 per share, showing a controlled burn rate.
CounterIn-line losses still mean continuous cash burn that must be funded by new capital.
Short interest of 16% is high, signaling sizeable bearish positioning against the stock.
↑Improving- Expectation
- Short interest declines as clinical evidence accumulates.
CounterHigh short interest can fuel a squeeze if the lead program reads out well.
Price is below the 200-day average, but that average is still rising at +4.3%/30d, a pullback in an uptrend after a -54% drawdown.
↓Deteriorating- Expectation
- Price reclaims the 200-day average while its slope stays positive.
CounterFalling on-balance volume shows distribution, and the momentum score of 3.4 reflects persistent selling.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 3.8 |
| OBV | 1.0 |
| MA position | 2.2 |
| Volume | 5.7 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+4.3%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.9 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 244%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Negligible insider buying — $20,008 (0.003% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.5 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 9.0 |
| support resistance | 9.7 |
| 52w position | 0.0 |
Risk (lower is worse)
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.9 |
| days to cover | 2.1 |
| volatility | 0.0 |
| put call | 9.8 |
| implied vol | 0.0 |
| beta | 10.0 |
| debt equity | 10.0 |
- ▸High short interest justified: 16%
- ▸High IV: 102%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Quality below minimum threshold.
Engine technical detail
L1:HARD_BLOCK:QUALITY_FLOOR- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:110d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
- MOMENTUM:3.4<4.5
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -54% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.4<4.5 outcome against Sentiment at 7.8 and asymmetric R:R of 0.00.
The strongest dimensions are Sentiment at 7.8, Insider at 7.3, and Technical at 6.2; the weakest are Quality at 1.6, Catalyst at 3.3, and Momentum at 3.4. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Asset Pipeline Concentration
Trip ifA second clinical program accounts for more than 20% of pipeline spending.
- P2Cash Burning Low Quality
Trip ifQuality score rises above 4.0 from the current 1.6.
- P3Predictable Loss Per Share
Trip ifQuarterly EPS loss exceeds $0.30 per share from the current $0.19.
- P4High Short Interest
Trip ifShort interest falls below 8% from the current 16%.
- P5Pullback In Uptrend
Trip ifThe 200-day moving average slope falls below 0%/30d from the current +4.3%/30d.